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linergic medications. The highest prevalence was seen for Level 1 medications 
(52.37%) followed by Level 2 (3.02%) and Level 3 (2.31%) medications. The preva-
lence of concurrent use of anticholinergic medications of various levels was 8.42% 
(7.53–9.32). Multinomial regression analysis revealed that predisposing (age) and need 
(behavioral symptoms, activities of daily living, out of bed mobility and depression) 
factors were positively associated with Level 1 drug use. Need factors (behavioral 
symptoms and total number of medications taken) were found to be negatively associ-
ated with Level 2 drug use whereas need factors like parkinsonism and depression 
were positively associated with receiving Level 3 medications and concurrent use, 
respectively. CONCLUSIONS: Nearly three of four elderly nursing home residents 
with dementia received anticholinergic medications of different levels. The ﬁndings 
suggest that there is a need to optimize anticholinergic medications in dementia 
patients, especially the higher level agents due to their signiﬁcant adverse proﬁle in 
dementia patients.
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OBJECTIVES: Individuals with a serious mental illness (SMI) often experience recidi-
vistic patterns in the criminal justice system (CJS). It has been argued that the provision 
of mental health services can disrupt this pattern. We examined the impact of com-
munity based mental health services on the arrest patterns of adults with a SMI who 
became involved in the CJS in Pinellas County Florida and Harris County Texas. 
METHODS: We identiﬁed adults 18–64 years old in Florida and Texas with a SMI 
who spent at least one day in jail during an index year. Statewide and local administra-
tive data sets were used to document their patterns of arrests and utilization of health 
and mental health services over 3–4 year periods. Generalized estimating equations 
were used for count data to estimate the association of outpatient and ER/inpatient 
mental health contacts in a quarter and arrests in the subsequent quarter. Individual 
ﬁxed effects models were also estimated to account for unobserved time invariant 
factors correlated with treatment and the likelihood of arrest. RESULTS: We identiﬁed 
3769 and 8505 individuals in the Florida and Texas data sets respectively. In Florida, 
individuals receiving outpatient services in a quarter were 20% less likely to be 
arrested in the subsequent quarter. The effect was greater for misdemeanor than for 
felony arrests. Individuals receiving ER/inpatient services were 7% more likely to be 
arrested in the subsequent quarter, and 13% more likely to have a felony arrest. The 
association between outpatient mental health services and arrests was conﬁrmed by 
the individual ﬁxed effects model. Parallel analyses are underway using Texas data to 
determine if the relationships hold for different jurisdictions and time frames. 
CONCLUSIONS: Outpatient mental health services were associated with a decrease 
in the risk of arrests among groups of individuals with a SMI and criminal justice 
involvements.
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OBJECTIVES: Optimal treatment of major depressive disorder (MDD) includes the 
selection of an adequate antidepressant medication and its delivery at a fully thera-
peutic dose for adequate treatment duration. Many factors may inﬂuence a physician’s 
decision making with respect to antidepressant choice and appropriate dose level. This 
study examined the pretreatment predictors of high-dose prescription of duloxetine 
for MDD patients in the real world clinical setting. METHODS: In a large commercial 
managed-care claims database, 6,132 MDD patients, who were initiated on duloxetine 
between July 1, 2005 and June 30, 2006, had no prior prescription of duloxetine for 
6 months, and had continuous enrollment for both 12 months prior to and post initia-
tion, were included. The associations between demographics and pre-initiation clinical 
variables and the maximum prescribed duloxetine dose (high: > 60 mg/day; mid: 
60 mg/day) were examined by chi-square tests and logistic regression. RESULTS: Of 
the sample, 16.3% had a maximum prescribed duloxetine dose of less than 60 mg/
day; 59.3%, 60 mg/day; and 24.4%, >60 mg/day. Compared with mid-dose patients, 
high-dose patients were older; had more comorbidities of neuropathic pain, osteoar-
thritis, ﬁbromyalgia, drug dependence, and bipolar disorders; were more likely to be 
treated by psychiatrists; used more benzodiazepines, venlafaxine, atypical antipsychot-
ics, psychostimulants, and anticonvulsants; and had higher pharmacy and medical 
costs in the prior 1 year (All p values < .05). After adjustment for health plan type 
and geographic region of residence, the following factors were independently associ-
ated with high-dose prescription: older age (36–64 vs. 18–35 years, OR = 1.34–1.53), 
neuropathic pain (OR = 1.56), prior use of psychostimulants (OR = 1.32), benzodi-
azepines (OR = 1.22), venlafaxine (OR = 1.24), atypical antipsychotics (OR = 1.35), 
and physician specialty (psychiatrist vs. non-psychiatrist, OR = 1.54). CONCLU-
SIONS: Multiple demographic and clinical characteristics and prior costs are associ-
ated with a high-dose duloxetine prescription. High-dose treated patients may 
represent a group of complicated patients with high medical costs who need intensive 
treatment.
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OBJECTIVES: Bipolar disorder (BD) treatment guidelines state that antidepressants 
(ADs) may precipitate, or exacerbate manic or mixed episodes and generally recom-
mend tapering or discontinuing ADs for patients with recent acute manic or mixed 
episodes. This study assessed the association between continued AD use and BD-
related re-hospitalizations among BD patients. METHODS: Using the PharMetrics 
Patient-Centric Database from January 1, 2004–June 30, 2007, we identiﬁed adults 
with an acute psychiatric event (“index event”), deﬁned by hospitalizations, emergency 
room visits, or physician visits with a prescription for a new BD medication with a 
primary diagnosis of BD I mania or BD I mixed. All patients were required to be 
eligible for the 12 months before and after index event and have a BD-related hospi-
talization (any diagnosis of any BD subtype) in the pre-index period. Patients with 
schizophrenia at any time during the study period were excluded. Continued AD use 
was deﬁned using prescription drug claims as 30+ days of available AD therapy within 
120 days after the index event. Logistic regression—controlling for age, sex, geo-
graphic region, baseline comorbidities—was used to determine the association 
between continued AD use and post-index BD-related re-hospitalizations (any diag-
nosis of any BD subtype). RESULTS: A total of 2126 patients met study criteria (mean 
age, 44; 57% female). 433 BD patients (20.4%) were re-hospitalized within 1 year. 
Patients receiving continued AD therapy (31.5%) were signiﬁcantly more likely to be 
re-hospitalized (OR, 1.387; 95% CI, 1.102, 1.748) than those without continued use. 
Other predictors of increased risk of re-hospitalization included being female and 
baseline diagnoses of comorbid substance abuse and eating disorders. CONCLU-
SIONS: Continued AD use in manic or mixed BD may be inappropriate. In this study, 
AD use for 30+ days within 120 days after an acute episode was associated with 
greater risk of BD-related re-hospitalization.
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OBJECTIVES: To evaluate risk and predictors of hospitalization among commercially 
insured patients with bipolar I disorder. METHODS: Retrospective cohort analysis 
using the PharMetrics Patient-centric Database, including patients with ≥1 inpatient 
or ≥2 outpatient medical claims indicating bipolar I disorder and ≥1 prescription for 
an antipsychotic medication between 7/1/2005, and 3/31/2007. Patients were followed 
1 year from date of ﬁrst (index) antipsychotic prescription. Continuous health beneﬁt 
eligibility from 1 year before (baseline) through 1 year after (follow-up) index was 
required. Patients had to receive ≥1 additional antipsychotic claim during follow-up 
to ensure a treated population. Adherence was measured using medication possession 
ratio (number of outpatient-treated days divided by total number of outpatient days 
during follow-up). Multivariate logistic regressions were used to identify factors asso-
ciated with all-cause (AC) and psychiatric-related (PR) hospitalization. RESULTS: A 
total of 12,100 patients were eligible. Mean (±SD) patient age was 37.2 (±15.7) years, 
59.9% were female; 22.8% had baseline diagnoses of substance abuse, and 49.8% 
had other psychiatric conditions. During follow-up, 27.9% of patients had AC and 
25.3% had PR hospitalizations. On average (±SD), patients had 0.5 (±1.1) AC and 
0.4 (±1.0) PR hospitalizations. Baseline substance abuse or diagnosis of other psycho-
sis; use of antidepressants, anxiolytics, or anticholinergics; psychiatric hospitalization; 
and nonadherence to antipsychotic therapy during follow-up were associated with 
signiﬁcantly greater risk (P < 0.05) of AC and PR hospitalizations; age < 35 years was 
also associated with signiﬁcantly greater risk of PR hospitalization. Baseline anticon-
vulsant use was associated with signiﬁcantly lower risk of PR hospitalization. CON-
CLUSIONS: Several patient characteristics appeared to be associated with greater risk 
of hospitalization among commercially insured bipolar I patients receiving antipsy-
chotics. These ﬁndings may be useful to health plan administrators interested in tar-
geted interventions, though further research on the impact of such interventions is 
needed. Supported by funding from Ortho-McNeil Janssen Scientiﬁc Affairs, LLC.
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OBJECTIVES: Compare transitions between mild, moderate and severe health states, 
and to death or institutionalization for Alzheimer disease (AD) and non-AD dementia 
patients. METHODS: The National Alzheimer Coordinating Center’s Uniform Data 
Set (NACC-UDS) is a large, longitudinal dataset funded by the National Institute of 
Aging that includes AD and non-AD dementia patients, and non-demented controls. 
